Novo Nordisk A/S (NVO) 20-F2015 FY Annual report (foreign)

Filed: 10 Feb 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: ApS, Arabia, authorised, biannual, build, Canada, ceased, Center, Crimea, Crimean, differentiated, driven, driver, Eivind, exclusivity, facilitate, FlexPro, German, Globe, Insurance, interim, investigating, Islamic, Kolding, LATIN, leucocyte, membership, memorandum, monthly, National, negative, NovoMix®in, NovoMix®were, ofthe, partial, patient, Phone, Principal, producing, proof, Republic, requisite, Saudi, spare, stability, Steno, Sylvie, Tresiba®in, Vagifem, Vagifem®increased, Xultophy®and

Removed: actively, affiliate, asset, behaviour, Beijing, commentary, confidentiality, dealing, direct, ending, expanding, experience, focused, fractionation, geographic, Hannu, HR, illegal, increasingly, inflammation, Kaluga, letter, listing, plasma, procurement, proper, ref, rendered, Seattle, spent, tangible, unethical, Victoza, wholly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NVO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 15.3

Consent of independent registered public accounting firm

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-82318 and No. 333-83724) of Novo Nordisk A/S of our report dated February 2, 2016 relating to the Consolidated Financial Statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F.

/s/ PricewaterhouseCoopers

Statsautoriseret Revisionspartnerselskab

Copenhagen, Denmark

February 10, 2016

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.